CU22545A1
(es)
*
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
JPS6328427Y2
(de)
|
1979-06-28 |
1988-08-01 |
|
|
JPS5944869U
(ja)
|
1982-09-17 |
1984-03-24 |
近畿アルミニユ−ム工業株式会社 |
プレートの間隔修正工具を備えた蝶番
|
US4526988A
(en)
*
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
EP0154434B1
(de)
*
|
1984-02-17 |
1993-01-27 |
Genentech, Inc. |
Menschlicher Transformationswachstumsfaktor und Vorläufer oder Fragment hiervon, Zellen, DNA, Vektoren und Verfahren zu ihrer Herstellung, Zusammensetzungen und Produkte, die diese enthalten, sowie davon abgeleitete Antikörper und Diagnostizierverfahren
|
US4582789A
(en)
*
|
1984-03-21 |
1986-04-15 |
Cetus Corporation |
Process for labeling nucleic acids using psoralen derivatives
|
US4563417A
(en)
*
|
1984-08-31 |
1986-01-07 |
Miles Laboratories, Inc. |
Nucleic acid hybridization assay employing antibodies to intercalation complexes
|
CA1264738A
(en)
*
|
1984-12-04 |
1990-01-23 |
Eli Lilly And Company |
Treatment of tumors in mammals
|
JPS62168137A
(ja)
*
|
1985-12-20 |
1987-07-24 |
Fuji Photo Film Co Ltd |
ハロゲン化銀カラ−写真感光材料およびその処理方法
|
JPH07106295B2
(ja)
|
1986-07-22 |
1995-11-15 |
エーザイ株式会社 |
調湿剤
|
CA1339136C
(en)
|
1987-07-01 |
1997-07-29 |
Sailesh Amilal Varia |
Amorphous form of aztreonam
|
AU4128089A
(en)
*
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
US5143854A
(en)
*
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US4983615A
(en)
|
1989-06-28 |
1991-01-08 |
Hoechst-Roussel Pharmaceuticals Inc. |
Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
|
US5180818A
(en)
*
|
1990-03-21 |
1993-01-19 |
The University Of Colorado Foundation, Inc. |
Site specific cleavage of single-stranded dna
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
AU1248292A
(en)
*
|
1990-12-06 |
1992-07-08 |
Affymax Technologies N.V. |
Sequencing by hybridization of a target nucleic acid to a matrix of defined oligonucleotides
|
GB9105677D0
(en)
|
1991-03-19 |
1991-05-01 |
Ici Plc |
Heterocyclic compounds
|
US5367057A
(en)
*
|
1991-04-02 |
1994-11-22 |
The Trustees Of Princeton University |
Tyrosine kinase receptor flk-2 and fragments thereof
|
ES2108120T3
(es)
|
1991-05-10 |
1997-12-16 |
Rhone Poulenc Rorer Int |
Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
|
US5721237A
(en)
|
1991-05-10 |
1998-02-24 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
JPH04341454A
(ja)
|
1991-05-16 |
1992-11-27 |
Canon Inc |
シート収納装置
|
US5750376A
(en)
*
|
1991-07-08 |
1998-05-12 |
Neurospheres Holdings Ltd. |
In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
|
US5211951A
(en)
|
1991-07-24 |
1993-05-18 |
Merck & Co., Inc. |
Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
|
JPH08501203A
(ja)
*
|
1992-06-03 |
1996-02-13 |
ケイス・ウエスタン・リザーブ・ユニバーシティー |
生理活性物質を連続的に適用するための包帯
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
JPH06153952A
(ja)
|
1992-11-26 |
1994-06-03 |
Nobuaki Tamamaki |
微量未知二重鎖dna分子の増幅、標識を行うための前処理方法
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
JP2637899B2
(ja)
*
|
1993-05-19 |
1997-08-06 |
鹿島建設株式会社 |
プレストレストコンクリートの製造方法およびプレストレストコンクリート
|
US6027880A
(en)
*
|
1995-08-02 |
2000-02-22 |
Affymetrix, Inc. |
Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
|
EP0637863B1
(de)
|
1993-08-02 |
1999-01-20 |
Cooper Industries, Inc. |
Zündkerzenelektroden
|
US6156501A
(en)
|
1993-10-26 |
2000-12-05 |
Affymetrix, Inc. |
Arrays of modified nucleic acid probes and methods of use
|
DE4499552C1
(de)
|
1993-12-09 |
1997-07-17 |
Heinrich Dr Exner |
Adjuvans für Antigene, Verfahren zur Herstellung und Verwendung
|
JPH07176103A
(ja)
|
1993-12-20 |
1995-07-14 |
Canon Inc |
光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
|
GB9326136D0
(en)
|
1993-12-22 |
1994-02-23 |
Erba Carlo Spa |
Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
US6811779B2
(en)
*
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
US5607939A
(en)
|
1994-04-28 |
1997-03-04 |
Takeda Chemical Industries, Ltd. |
Condensed heterocyclic compounds, their production and use
|
JP3660391B2
(ja)
|
1994-05-27 |
2005-06-15 |
株式会社東芝 |
半導体装置の製造方法
|
JPH0848078A
(ja)
|
1994-08-05 |
1996-02-20 |
Nippon Paper Ind Co Ltd |
感熱記録体
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
US5656454A
(en)
*
|
1994-10-04 |
1997-08-12 |
President And Fellows Of Harvard College |
Endothelial cell-specific enhancer
|
IL115256A0
(en)
*
|
1994-11-14 |
1995-12-31 |
Warner Lambert Co |
6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
|
JP3081477B2
(ja)
|
1994-11-28 |
2000-08-28 |
三洋電機株式会社 |
プリント基板の絶縁方法
|
JPH08176138A
(ja)
|
1994-12-19 |
1996-07-09 |
Mercian Corp |
イソクマリン誘導体
|
US5948438A
(en)
*
|
1995-01-09 |
1999-09-07 |
Edward Mendell Co., Inc. |
Pharmaceutical formulations having improved disintegration and/or absorptivity
|
US5556496A
(en)
|
1995-01-10 |
1996-09-17 |
Sumerak; Joseph E. |
Pultrusion method for making variable cross-section thermoset articles
|
US5658374A
(en)
|
1995-02-28 |
1997-08-19 |
Buckman Laboratories International, Inc. |
Aqueous lecithin-based release aids and methods of using the same
|
US5624937A
(en)
*
|
1995-03-02 |
1997-04-29 |
Eli Lilly And Company |
Chemical compounds as inhibitors of amyloid beta protein production
|
DK0817775T3
(da)
|
1995-03-30 |
2001-11-19 |
Pfizer |
Quinazolinderivater
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5880141A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
JP3290666B2
(ja)
|
1995-06-07 |
2002-06-10 |
ファイザー・インコーポレーテッド |
複素環式の縮合環ピリミジン誘導体
|
JPH0923885A
(ja)
|
1995-07-12 |
1997-01-28 |
Dai Ichi Seiyaku Co Ltd |
遺伝子発現ライブラリー及びその製造法
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
AU7340096A
(en)
*
|
1995-11-07 |
1997-05-29 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
|
US5849759A
(en)
|
1995-12-08 |
1998-12-15 |
Berlex Laboratories, Inc. |
Naphthyl-substituted benzimidazole derivatives as anti-coagulants
|
GB9604361D0
(en)
|
1996-02-29 |
1996-05-01 |
Pharmacia Spa |
4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
|
JPH09234074A
(ja)
|
1996-03-04 |
1997-09-09 |
Sumitomo Electric Ind Ltd |
アダプター二本鎖dna及びそれを用いたdna増幅方法
|
IL126610A0
(en)
|
1996-04-17 |
1999-08-17 |
Du Pont Pharm Co |
N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3- one derivatives as factor xa inhibitors
|
AU3568897A
(en)
*
|
1996-06-07 |
1998-01-05 |
Eos Biotechnology, Inc. |
Immobilised linear oligonucleotide arrays
|
JP2000514061A
(ja)
|
1996-06-28 |
2000-10-24 |
メルク エンド カンパニー インコーポレーテッド |
フィブリノーゲン受容体拮抗物質
|
US6391874B1
(en)
|
1996-07-13 |
2002-05-21 |
Smithkline Beecham Corporation |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
PL331154A1
(en)
|
1996-07-13 |
1999-06-21 |
Glaxo Group Ltd |
Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
|
AU733551B2
(en)
|
1996-09-25 |
2001-05-17 |
Astrazeneca Ab |
Qinoline derivatives inhibiting the effect of growth factors such as VEGF
|
CA2268129C
(en)
|
1996-09-30 |
2003-03-11 |
Nihon Nohyaku Co., Ltd. |
1,2,3-thiadiazole derivatives or salts thereof and agrohorticultural disease controller and method for using the same
|
EP0837063A1
(de)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazolinderivate
|
IL129825A0
(en)
|
1996-11-27 |
2000-02-29 |
Pfizer |
Fused bicyclic pyrimidine derivatives
|
EP1014971A1
(de)
|
1997-01-29 |
2000-07-05 |
Eli Lilly And Company |
Behandlung von prämenstruelle dysphorische störung
|
JP3040486U
(ja)
|
1997-02-13 |
1997-08-19 |
有限会社ザップ |
フィッシングジャケット
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
PL335235A1
(en)
|
1997-02-19 |
2000-04-10 |
Berlex Lab |
N-heterocyclic derivatives as nos inhibitors
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
WO1998050346A2
(en)
|
1997-04-18 |
1998-11-12 |
Smithkline Beecham Plc |
Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
|
PT1019040E
(pt)
|
1997-05-23 |
2005-01-31 |
Bayer Pharmaceuticals Corp |
Inibicao da actividade de p38-quinase por meio de arilureias
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
WO1999001738A2
(en)
|
1997-06-30 |
1999-01-14 |
University Of Maryland, Baltimore |
Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
|
JP3765918B2
(ja)
*
|
1997-11-10 |
2006-04-12 |
パイオニア株式会社 |
発光ディスプレイ及びその駆動方法
|
JP4194678B2
(ja)
|
1997-11-28 |
2008-12-10 |
キリンファーマ株式会社 |
キノリン誘導体およびそれを含む医薬組成物
|
KR100253378B1
(ko)
*
|
1997-12-15 |
2000-04-15 |
김영환 |
주문형반도체의외부표시장치
|
DE69836563T2
(de)
|
1997-12-22 |
2007-05-16 |
Bayer Pharmaceuticals Corp., West Haven |
INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
|
BR9814374B1
(pt)
|
1997-12-22 |
2013-09-17 |
|
"urÉias heterocÍclicas substituÍdas e composiÇÕes compreendendo as mesmas"
|
RU2247109C9
(ru)
|
1997-12-22 |
2005-06-20 |
Байер Копэрейшн |
Симметричные и несимметричные производные дифенилмочевины (варианты), фармацевтическая композиция, способ подавления роста опухолевых клеток, опосредованного киназой raf
|
IL136738A0
(en)
|
1997-12-22 |
2001-06-14 |
Bayer Ag |
Inhibition of p38 kinase activity using substituted heterocyclic ureas
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
GEP20032920B
(en)
|
1998-02-25 |
2003-03-25 |
Genetics Inst |
Inhibitors of Phospholipase Enzymes
|
JPH11322596A
(ja)
|
1998-05-12 |
1999-11-24 |
Shionogi & Co Ltd |
白金錯体および環状リン酸エステルアミドを含有する抗癌剤
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
IL143089A0
(en)
|
1998-11-19 |
2002-04-21 |
Warner Lambert Co |
N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
CN1183114C
(zh)
|
1999-01-22 |
2005-01-05 |
麒麟麦酒株式会社 |
喹啉衍生物及喹唑啉衍生物
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
IL144745A0
(en)
|
1999-02-10 |
2002-06-30 |
Astrazeneca Ab |
Quinazoline derivatives as angiogenesis inhibitors
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
JP2000328080A
(ja)
|
1999-03-12 |
2000-11-28 |
Shin Etsu Chem Co Ltd |
シートベルト用低摩擦化処理剤
|
RS49836B
(sr)
*
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
EP1185559A2
(de)
*
|
1999-04-28 |
2002-03-13 |
Board Of Regents, The University Of Texas System |
Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
|
WO2000071097A1
(fr)
|
1999-05-20 |
2000-11-30 |
Takeda Chemical Industries, Ltd. |
Composition contenant du sel d'acide ascorbique
|
JP4304357B2
(ja)
|
1999-05-24 |
2009-07-29 |
独立行政法人理化学研究所 |
完全長cDNAライブラリーの作成法
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
AU6762400A
(en)
*
|
1999-08-12 |
2001-03-13 |
Cor Therapeutics, Inc. |
Inhibitors of factor xa
|
DOP2000000070A
(es)
|
1999-09-28 |
2002-02-28 |
Bayer Healthcare Llc |
Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
|
UA75054C2
(uk)
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
|
JP2001131071A
(ja)
|
1999-10-29 |
2001-05-15 |
Meiji Seika Kaisha Ltd |
非晶質および非晶質を含有する医薬組成物
|
AU784338B2
(en)
|
1999-11-01 |
2006-03-16 |
Curagen Corporation |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
US20080241835A1
(en)
*
|
1999-11-01 |
2008-10-02 |
Genentech, Inc. |
Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
|
WO2001036403A1
(en)
|
1999-11-16 |
2001-05-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Urea derivatives as anti-inflammatory agents
|
US6274638B1
(en)
|
1999-11-19 |
2001-08-14 |
Nippon Shokubai Co., Ltd. |
Method for production of porous cross-linked polymer material
|
UA75055C2
(uk)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
WO2001045889A1
(fr)
|
1999-12-20 |
2001-06-28 |
Mitsubishi Denki Kabushiki Kaisha |
Procede et dispositif d'usinage par etincelage
|
MXPA02006263A
(es)
|
1999-12-22 |
2004-02-26 |
Sugen Inc |
Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona.
|
AU2223501A
(en)
|
1999-12-24 |
2001-07-09 |
Kyowa Hakko Kogyo Co. Ltd. |
Fused purine derivatives
|
AU2223201A
(en)
*
|
1999-12-24 |
2001-07-09 |
Kirin Beer Kabushiki Kaisha |
Quinoline and quinazoline derivatives and drugs containing the same
|
AR034118A1
(es)
*
|
2000-02-15 |
2004-02-04 |
Sugen Inc |
Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
|
JP3657203B2
(ja)
*
|
2000-04-21 |
2005-06-08 |
エーザイ株式会社 |
銅クロロフィリン塩含有液剤組成物
|
JP2004512023A
(ja)
*
|
2000-06-09 |
2004-04-22 |
コリクサ コーポレイション |
結腸癌の治療および診断のための組成物および方法
|
JP4033605B2
(ja)
*
|
2000-06-19 |
2008-01-16 |
ライオン株式会社 |
エアゾール型制汗剤組成物
|
WO2002016348A1
(en)
|
2000-08-09 |
2002-02-28 |
Astrazeneca Ab |
Antiangiogenic bicyclic derivatives
|
EP1313723B1
(de)
|
2000-08-24 |
2006-03-01 |
Union Carbide Chemicals & Plastics Technology Corporation |
Verfahren zur herstellung von laktonen
|
EP1506962B1
(de)
|
2000-10-20 |
2008-07-02 |
Eisai R&D Management Co., Ltd. |
Stickstoff enthaltende aromatische Heterozyklen
|
TWI283575B
(en)
*
|
2000-10-31 |
2007-07-11 |
Eisai Co Ltd |
Medicinal compositions for concomitant use as anticancer agent
|
PT1339458E
(pt)
*
|
2000-11-22 |
2007-11-09 |
Novartis Ag |
Combinação compreendendo um agente para diminuir a actividade do vegf e um agente para diminuir a actividade do egf
|
AU2002232439A1
(en)
|
2000-11-29 |
2002-06-11 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
AU2002247248B2
(en)
*
|
2001-03-02 |
2007-07-05 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
PCR method
|
US6960580B2
(en)
|
2001-03-08 |
2005-11-01 |
Millennium Pharmaceuticals, Inc. |
Nitrogenous heterocyclic substituted quinoline compounds
|
SI1385551T1
(sl)
|
2001-04-06 |
2008-12-31 |
Wyeth Five Giralda Farms |
Antineoplastiäśne kombinacije, ki vsebujejo cci-779 (derivat rapamicina) skupaj z gemcitabinom ali fluorouracilom
|
WO2002085926A2
(de)
*
|
2001-04-19 |
2002-10-31 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
|
US6821987B2
(en)
|
2001-04-27 |
2004-11-23 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives having azolyl group
|
JP3602513B2
(ja)
|
2001-04-27 |
2004-12-15 |
麒麟麦酒株式会社 |
アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
|
JP2003026576A
(ja)
*
|
2001-05-09 |
2003-01-29 |
Eisai Co Ltd |
味覚改善製剤
|
US6812341B1
(en)
|
2001-05-11 |
2004-11-02 |
Ambion, Inc. |
High efficiency mRNA isolation methods and compositions
|
ATE359790T1
(de)
|
2001-05-16 |
2007-05-15 |
Novartis Pharma Gmbh |
Kombination von n- 5- 4-(4-methyl-piperazino- methyl)-benzoylamido -2-methylphenyl -4-(3- pyridil)-2pyrimidine-amin mit einem biphosphonat
|
KR100883731B1
(ko)
|
2001-06-22 |
2009-02-12 |
기린 파마 가부시끼가이샤 |
간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
|
GB0117144D0
(en)
|
2001-07-13 |
2001-09-05 |
Glaxo Group Ltd |
Process
|
US20030013208A1
(en)
*
|
2001-07-13 |
2003-01-16 |
Milagen, Inc. |
Information enhanced antibody arrays
|
JP4827154B2
(ja)
|
2001-07-25 |
2011-11-30 |
株式会社オーイズミ |
遊技装置
|
GB0119467D0
(en)
|
2001-08-09 |
2001-10-03 |
Smithkline Beecham Plc |
Novel compound
|
US7063946B2
(en)
*
|
2001-09-10 |
2006-06-20 |
Meso Scale Technologies, Llc. |
Methods, reagents, kits and apparatus for protein function analysis
|
CA2461812C
(en)
|
2001-09-27 |
2011-09-20 |
Allergan, Inc. |
3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
|
US20040266779A1
(en)
|
2001-09-27 |
2004-12-30 |
Anderson Kenneth C. |
Use of c-kit inhibitors for the treatment of myeloma
|
US20040191254A1
(en)
*
|
2001-10-09 |
2004-09-30 |
Fagin James Alexander |
Method of treatment of thyroid cancer
|
US7495104B2
(en)
*
|
2001-10-17 |
2009-02-24 |
Kirin Beer Kabushiki Kaisha |
Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
|
US6821988B2
(en)
|
2001-11-27 |
2004-11-23 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
|
GB0201508D0
(en)
*
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
EP1481678A4
(de)
*
|
2002-03-05 |
2009-12-30 |
Eisai R&D Man Co Ltd |
Antitumorales mittel mit einer kombination aus einer sulfonamid-haltigen heterocyclischen verbindung und einem angiogenese-hemmer
|
EP1488239A2
(de)
|
2002-03-20 |
2004-12-22 |
Dana-Farber Cancer Institute, Inc. |
Verfahren und verbindungen für die identifizierung, nachweis und behandlung von kleinzellen-lungenkarzinom
|
AU2003235838A1
(en)
|
2002-05-01 |
2003-11-17 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
|
UA77303C2
(en)
*
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
WO2004006862A2
(en)
|
2002-07-16 |
2004-01-22 |
Children's Medical Center Corporation |
A method for the modulation of angiogenesis
|
US7169936B2
(en)
*
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
US7252976B2
(en)
*
|
2002-08-28 |
2007-08-07 |
Board Of Regents The University Of Texas System |
Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
|
AU2003261807B9
(en)
|
2002-08-30 |
2007-02-15 |
Eisai R & D Management Co., Ltd. |
Azaarene derivatives
|
AU2003279923A1
(en)
|
2002-10-09 |
2004-05-04 |
Kosan Biosciences, Inc. |
Epo D + 5-FU/GEMCITABINE
|
GB0223380D0
(en)
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
AU2003273000A1
(en)
|
2002-10-16 |
2004-05-04 |
Takeda Pharmaceutical Company Limited |
Stable solid preparations
|
JP4749660B2
(ja)
*
|
2002-10-16 |
2011-08-17 |
武田薬品工業株式会社 |
安定な固形製剤
|
EP1556356B1
(de)
|
2002-10-21 |
2006-05-31 |
Warner-Lambert Company LLC |
Tetrahydrochinolin-derivate als crth2 antagonisten
|
JPWO2004039782A1
(ja)
|
2002-10-29 |
2006-03-02 |
麒麟麦酒株式会社 |
Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
|
DE10250711A1
(de)
*
|
2002-10-31 |
2004-05-19 |
Degussa Ag |
Pharmazeutische und kosmetische Zubereitungen
|
GB0225535D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
AU2003276453A1
(en)
|
2002-11-06 |
2004-06-07 |
Cyclacel Limited |
Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
|
GB0226434D0
(en)
|
2002-11-13 |
2002-12-18 |
Astrazeneca Ab |
Combination product
|
AR042042A1
(es)
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
CA2511970C
(en)
|
2003-01-14 |
2012-06-26 |
Cytokinetics, Inc. |
Urea derivatives useful in the treatment of heart failure
|
US6944063B2
(en)
|
2003-01-28 |
2005-09-13 |
Sandisk Corporation |
Non-volatile semiconductor memory with large erase blocks storing cycle counts
|
JP3581361B1
(ja)
|
2003-02-17 |
2004-10-27 |
株式会社脳機能研究所 |
脳活動測定装置
|
CN1780811A
(zh)
|
2003-03-05 |
2006-05-31 |
细胞基因公司 |
二苯基乙烯化合物及其用途
|
EP1604665B1
(de)
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase-hemmer
|
ITMI20030479A1
(it)
|
2003-03-13 |
2004-09-14 |
Adorkem Technology S P A |
Procedimento per la preparazione di un ciano-isobenzofurano.
|
JP4736043B2
(ja)
*
|
2003-03-14 |
2011-07-27 |
小野薬品工業株式会社 |
含窒素複素環誘導体およびそれらを有効成分とする薬剤
|
JPWO2004081047A1
(ja)
*
|
2003-03-14 |
2006-06-29 |
大正製薬株式会社 |
モノクローナル抗体及びこれを産生するハイブリドーマ
|
US20070117842A1
(en)
*
|
2003-04-22 |
2007-05-24 |
Itaru Arimoto |
Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same
|
JP2005008534A
(ja)
|
2003-06-17 |
2005-01-13 |
Soc De Conseils De Recherches & D'applications Scientifiques (Scras) |
抗癌剤及び癌の治療方法
|
KR20060033782A
(ko)
|
2003-07-10 |
2006-04-19 |
아스트라제네카 아베 |
백금 화합물 및 임의적으로 이온화 방사능과 조합된퀴나졸린 유도체 zd6474의 혈관신생 및/또는 증가된 혈관투과성 관련 질환 치료 용도
|
EP1653934B1
(de)
*
|
2003-08-15 |
2008-05-14 |
AB Science |
Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
|
US7485658B2
(en)
*
|
2003-08-21 |
2009-02-03 |
Osi Pharmaceuticals, Inc. |
N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
|
US7521448B2
(en)
*
|
2003-08-21 |
2009-04-21 |
Osi Pharmaceuticals, Inc. |
N-substituted benzimidazolyl c-Kit inhibitors
|
MXPA06002017A
(es)
|
2003-08-21 |
2006-05-31 |
Osi Pharm Inc |
Pirazolil-amidil-bencimidazolilo n-sustituidos, ibnhibidores de c-kit.
|
EA200600495A1
(ru)
|
2003-09-23 |
2006-10-27 |
Новартис Аг |
Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
|
PL2210607T3
(pl)
|
2003-09-26 |
2012-01-31 |
Exelixis Inc |
N-[3-fluoro-4-({6-(metyloksy)-7-[(3-morfolin-4-ylopropylo)oksy]chinolin-4-ylo} oxy)fenylo]-N'-(4-fluorofenylo)cyklopropano-1,1-dikarboksamid do leczenia raka
|
CN100450998C
(zh)
*
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
US20080312192A1
(en)
|
2003-11-28 |
2008-12-18 |
Guido Bold |
Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases
|
SG149004A1
(en)
|
2003-12-05 |
2009-01-29 |
Bristol Myers Squibb Co |
Inhibitors of type 2 vascular endothelial growth factor receptors
|
PT1698623E
(pt)
*
|
2003-12-25 |
2015-06-29 |
Eisai R&D Man Co Ltd |
Cristal de sal de 4-(3-cloro-4-(ciclopropilaminocarbonil)amino fenoxi)-7-metoxi-6-quinolinacarboxamida ou de seu solvato e rocesso para produção destes
|
KR100799535B1
(ko)
|
2004-02-27 |
2008-01-31 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
신규 피리딘 유도체 및 피리미딘 유도체(2)
|
KR20050091462A
(ko)
|
2004-03-12 |
2005-09-15 |
한국과학기술연구원 |
푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
|
NZ551406A
(en)
|
2004-06-03 |
2010-03-26 |
Hoffmann La Roche |
Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)
|
US20050288521A1
(en)
|
2004-06-29 |
2005-12-29 |
Phytogen Life Sciences Inc. |
Semi-synthetic conversion of paclitaxel to docetaxel
|
WO2006029193A2
(en)
*
|
2004-09-08 |
2006-03-16 |
Pacific Scientific Energetic Materials Company |
Process for preparing substituted tetrazoles from aminotetrazole
|
US8772269B2
(en)
*
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
WO2006030947A1
(ja)
|
2004-09-13 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
スルホンアミド含有化合物の血管新生阻害物質との併用
|
WO2006030826A1
(ja)
|
2004-09-17 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
医薬組成物
|
EP1794137A4
(de)
|
2004-09-27 |
2009-12-02 |
Kosan Biosciences Inc |
Spezifische kinase-hemmer
|
CA2586420A1
(en)
|
2004-11-22 |
2007-04-12 |
King Pharmaceuticals Research & Development, Inc. |
Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
|
JP2008523072A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ, インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
RS51821B
(en)
|
2005-02-28 |
2012-02-29 |
Eisai R. &D. Management Co. Ltd. |
NEW COMBINED USE OF SULFONAMIDE UNITS IN CANCER TREATMENT
|
EP1859797A4
(de)
|
2005-02-28 |
2011-04-13 |
Eisai R&D Man Co Ltd |
Neue gleichzeitige verwendung einer sulfonamid-verbindung und eines mittels gegen krebs
|
CA2608733A1
(en)
|
2005-05-17 |
2007-02-01 |
Plexxikon, Inc. |
Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
|
US7369245B2
(en)
|
2005-05-27 |
2008-05-06 |
Honeywell International, Inc. |
Sensing coil assembly and method for attaching a sensing coil in a fiber optic gyroscope
|
SI2395004T1
(sl)
|
2005-06-22 |
2016-05-31 |
Plexxikon Inc. |
Derivati piro (2,3-b) piridina kot inhibitorji proteinske kinaze
|
US7550483B2
(en)
*
|
2005-06-23 |
2009-06-23 |
Eisai R&D Management Co., Ltd. |
Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
|
JP4733700B2
(ja)
|
2005-06-23 |
2011-07-27 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
4−(3−クロロ−4−(シクロプロピルアミノカルボニル)アミノフェノキシ)−7−メトキシ−6−キノリンカルボキサミドの塩のアモルファスおよびその製造方法
|
WO2007000347A2
(en)
|
2005-06-29 |
2007-01-04 |
Roselli, Patrizia |
Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
US20080219977A1
(en)
|
2005-07-27 |
2008-09-11 |
Isaiah Josh Fidler |
Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
|
US20100105031A1
(en)
*
|
2005-08-01 |
2010-04-29 |
Esai R & D Management Co., Ltd. |
Method for prediction of the efficacy of vascularization inhibitor
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
RU2362771C1
(ru)
|
2005-08-24 |
2009-07-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Новое производное пиридина и производное пиримидина (3)
|
JPWO2007052849A1
(ja)
|
2005-11-07 |
2009-04-30 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質とc−kitキナーゼ阻害物質との併用
|
US20090247576A1
(en)
*
|
2005-11-22 |
2009-10-01 |
Eisai R & D Management Co., Ltd. |
Anti-tumor agent for multiple myeloma
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
KR100728926B1
(ko)
|
2006-03-20 |
2007-06-15 |
삼성전자주식회사 |
3축 힌지 구조를 갖는 휴대용 전자기기
|
CN101443009A
(zh)
*
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
EP2062886B1
(de)
|
2006-08-23 |
2011-11-30 |
Eisai R&D Management Co., Ltd. |
Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
EP2061331A4
(de)
|
2006-09-05 |
2010-02-24 |
Mcneil Nutritionals Llc |
Lactasehaltige essbare produkte und entsprechende verfahren
|
KR20080022761A
(ko)
|
2006-09-07 |
2008-03-12 |
삼성전자주식회사 |
화상형성장치의 화소간 정렬 오류 검출 장치 및 방법
|
AU2008205847A1
(en)
|
2007-01-19 |
2008-07-24 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of pancreatic cancer
|
CN101663279A
(zh)
|
2007-01-19 |
2010-03-03 |
阿迪生物科学公司 |
Mek抑制剂
|
JP5319306B2
(ja)
|
2007-01-29 |
2013-10-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
未分化型胃癌治療用組成物
|
KR20090116794A
(ko)
|
2007-03-05 |
2009-11-11 |
교와 핫꼬 기린 가부시키가이샤 |
의약 조성물
|
KR20090115866A
(ko)
|
2007-03-05 |
2009-11-09 |
교와 핫꼬 기린 가부시키가이샤 |
의약 조성물
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
CA2924418A1
(en)
|
2007-07-30 |
2009-02-05 |
Jean-Michel Vernier |
Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
|
CN101848895B
(zh)
*
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
JP2009132660A
(ja)
|
2007-11-30 |
2009-06-18 |
Eisai R & D Management Co Ltd |
食道癌治療用組成物
|
MX2010008187A
(es)
|
2008-01-29 |
2010-08-10 |
Eisai R&D Man Co Ltd |
Uso combinado de inhibidor de angiogenesis y taxano.
|
GB2456907A
(en)
|
2008-01-30 |
2009-08-05 |
Astrazeneca Ab |
Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level.
|
AU2009221765B2
(en)
*
|
2008-03-05 |
2015-05-07 |
Vicus Therapeutics, Llc |
Compositions and methods for mucositis and oncology therapies
|
US8044240B2
(en)
|
2008-03-06 |
2011-10-25 |
Ardea Biosciences Inc. |
Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
|
EP2291350A4
(de)
|
2008-04-14 |
2012-09-19 |
Ardea Biosciences Inc |
Zusammensetzungen und verfahren zu ihrer herstellung und verwendung
|
JP5699075B2
(ja)
|
2008-05-14 |
2015-04-08 |
アムジエン・インコーポレーテツド |
癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ
|
WO2009150256A1
(en)
|
2008-06-13 |
2009-12-17 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Markers for predicting response and survival in anti-egfr treated patients
|
CA2729914A1
(en)
|
2008-07-11 |
2010-01-14 |
Novartis Ag |
Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
|
EP2350663A2
(de)
|
2008-10-21 |
2011-08-03 |
Bayer HealthCare LLC |
Identifizierung von signaturgenen in zusammenhang mit hepatozellulärem karzinom
|
US20120164148A1
(en)
|
2009-08-07 |
2012-06-28 |
The Wistar Institute |
Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer
|
ES2564797T3
(es)
|
2009-08-19 |
2016-03-29 |
Eisai R&D Management Co., Ltd. |
Composición farmacéutica con contenido en un derivado de quinolina
|
JP2013502421A
(ja)
|
2009-08-21 |
2013-01-24 |
マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー |
癌治療のためのcd44融合タンパク質の使用方法
|
EP2293071A1
(de)
|
2009-09-07 |
2011-03-09 |
Universität Zu Köln |
Biomarker für kolorektalen Krebs
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
US9133162B2
(en)
*
|
2011-02-28 |
2015-09-15 |
Sunshine Lake Pharma Co., Ltd. |
Substituted quinoline compounds and methods of use
|
CA2864394C
(en)
*
|
2011-03-02 |
2021-10-19 |
Jack Roth |
A method of predicting a response to a tusc2 therapy
|
WO2012122444A1
(en)
*
|
2011-03-10 |
2012-09-13 |
Provectus Pharmaceuticals, Inc. |
Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
|
EP3444363B1
(de)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
|